

## Special Issue on **Cellular Therapies in VCA**

# CALL FOR PAPERS

Vascularized composite allotransplantation (VCA) has emerged as a viable reconstructive option for individuals suffering from devastating tissue loss not amenable to traditional reconstructive techniques, such as the hand or face transplantation. Although technically feasible, broader clinical application of VCA is limited by the lifelong immunosuppression and need for a good and fast nerve regeneration for a functional allograft. Cellular therapies are one of the important strategies used both experimentally and clinically to overcome these drawbacks of VCA.

In this special issue, we want to address the cell-based approaches to VCA, especially in terms of tolerance induction and nerve regeneration in both the laboratory and the clinical setting. We are hoping to include not only stem cell-based therapies in VCA but other types of cells that are used for immunomodulation such as dendritic cells and Tregs. We will be accepting research and review articles about cellular therapies describing the current state of the art.

Potential topics include but are not limited to the following:

- ▶ Stem cell applications for immunomodulation in VCA (ASC, BM-MSC, AD-MSC, iPSC, and amniotic or placental derived stem cells)
- ▶ Usage of Treg cells in VCA
- ▶ Dendritic cells and skin containing VCA
- ▶ Chimeric cell applications in VCA
- ▶ Cell free therapies such as exosomes in immunomodulation
- ▶ Cellular therapies for nerve regeneration in VCA
- ▶ Clinical applications of cell based therapies in VCA
- ▶ Cell tracking strategies for immunomodulatory therapies

Authors can submit their manuscripts through the Manuscript Tracking System at <https://mts.hindawi.com/submit/journals/jtrans/ctvca/>.

Papers are published upon acceptance, regardless of the Special Issue publication date.

### Lead Guest Editor

Vijay S. Gorantla, Wake Forest Institute for Regenerative Medicine, Winston-Salem, USA  
*vgorantl@wakehealth.edu*

### Guest Editors

Fatih Zor, Wake Forest Institute for Regenerative Medicine, Winston-Salem, USA  
*fzor@wakehealth.edu*

Yalcin Kulahci, University of Pittsburgh, Pittsburgh, USA  
*yak37@pitt.edu*

### Submission Deadline

Friday, 27 April 2018

### Publication Date

September 2018